CoChat

Role of neuroinflammation in neurodegeneration development

Open access
Zhang, Weifeng, Xiao, Dan, Mao, Qinwen, Xia, Haibin · 2023 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 587 of the 590 references it cites were found in a registry or an index; 359 of the 564 sources its claims cite were checked for support.

Abstract

Studies in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and Amyotrophic lateral sclerosis, Huntington's disease, and so on, have suggested that inflammation is not only a result of neurodegeneration but also a crucial player in this process. Protein aggregates which are very common pathological phenomenon in neurodegeneration can induce neuroinflammation which further aggravates protein aggregation and neurodegeneration. Actually, inflammation even happens earlier than protein aggregation. Neuroinflammation induced by genetic variations in CNS cells or by peripheral immune cells may induce protein deposition in some susceptible population. Numerous signaling pathways and a range of CNS cells have been suggested to be involved in the pathogenesis of neurodegeneration, although they are still far from being completely understood. Due to the limited success of traditional treatment methods, blocking or enhancing inflammatory signaling pathways involved in neurodegeneration are considered to be promising strategies for the therapy of neurodegenerative diseases, and many of them have got exciting results in animal models or clinical trials. Some of them, although very few, have been approved by FDA for clinical usage. Here we comprehensively review the factors affecting neuroinflammation and the major inflammatory signaling pathways involved in the pathogenicity of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Amyotrophic lateral sclerosis. We also summarize the current strategies, both in animal models and in the clinic, for the treatment of neurodegenerative diseases.

Overview

CoChat Summary

TL;DR

This review argues that neuroinflammation is not just a downstream consequence of neurodegeneration, but can begin early and help drive disease progression in AD, PD, and ALS. It synthesizes evidence on inflammatory triggers, signaling pathways, and immune-directed therapies, while emphasizing that many inflammatory targets have both harmful and protective roles depending on timing and context.

Key findings

  • The paper states that neuroinflammation is a shared hallmark across major neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), and may occur before overt protein aggregation.
  • In AD, the review notes that more than 10% of people older than 65 and 30% of people older than 85 are affected; it also states that ~90–95% of AD is sporadic, while early-onset AD accounts for up to 5% of cases.
  • In PD, the paper reports that at diagnosis about 30% of dopaminergic neuronal cell bodies in the substantia nigra and 50% of dopamine axon terminals in the dorsal putamen have already been lost; by 4 years after diagnosis almost all dopamine axon terminals are lost, and by 5 years most neuronal cell bodies are lost.
  • In TBI, the review reports diffuse Aβ plaques in the brains of 30% of individuals who acutely die from TBI, and says TBI is a risk factor for PD and ALS.
  • The paper highlights several therapeutic findings: aducanumab was approved by the US FDA in 2021, lecanemab in January 2023, and edaravone was approved in Japan in 2015 and the US in 2017 for ALS.

Methods

  • Narrative review of the role of neuroinflammation in neurodegeneration, focused on AD, PD, and ALS, with sections on endogenous, environmental, and genetic inflammatory triggers, signaling pathways, and immune-directed therapies.
  • The paper synthesizes findings from clinical studies, GWAS, postmortem human tissue studies, animal models, and in vitro experiments; no original cohort or experimental dataset is presented.
  • Main analysis is qualitative integration of prior literature, including comparisons across disease stages and discussion of pro-inflammatory and pro-resolving signaling.

Limitations

  • The paper explicitly states that many mechanisms are “still far from being completely understood” and that further studies are needed to clarify signaling roles, especially for pathways such as cGAS-STING, TLRs, RAGE, TREM2, NLRP3, and NO.
  • It also states that many therapies show effects in animal models or early trials but have limited clinical success or no confirmed clinical benefit yet.
  • Evident from the text: this is a review article, so it cannot establish causality on its own and relies on heterogeneous prior studies, often with conflicting results across models and disease stages.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41392-023-01486-5

Cites

587 of 587 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 The role of inflammation in neurodegeneration. Inflammatory receptors on the surface of immune cells, especially glial cells, act as sensors to detect abnormality in the human body. Stimulation of the sensors by DAMPs or PAMPs, such as protein aggregates, virus, bacteria, leads to activation of signal transducers which then activate transcription activators. Subsequently, activated transcription factors induce the secretion of inflammatory mediators which further amplify inflammation. Generally, activated glial cells should kill the dangers and then induce an inflammation resolution process to clear the DAMPs or PAMPs and stop inflammatory response. However, owing to some reasons, activated immune cells fail to resolve inflammation and generate chronic inflammation which cause neuronal toxicity and enhance protein aggregation. Protein aggregates and DAMPs released from damaged neurons further amplify neuroinflammation and aggravate disease. Some protein aggregates, such as TDP-43 and α-synuclein, may even invade mitochondria which can induce death of neuron directly
Fig. 1 The role of inflammation in neurodegeneration. Inflammatory receptors on the surface of immune cells, especially glial cells, act as sensors to detect abnormality in the human body. Stimulation of the sensors by DAMPs or PAMPs, such as protein aggregates, virus, bacteria, leads to activation of signal transducers which then activate transcription activators. Subsequently, activated transcription factors induce the secretion of inflammatory mediators which further amplify inflammation. Generally, activated glial cells should kill the dangers and then induce an inflammation resolution process to clear the DAMPs or PAMPs and stop inflammatory response. However, owing to some reasons, activated immune cells fail to resolve inflammation and generate chronic inflammation which cause neuronal toxicity and enhance protein aggregation. Protein aggregates and DAMPs released from damaged neurons further amplify neuroinflammation and aggravate disease. Some protein aggregates, such as TDP-43 and α-synuclein, may even invade mitochondria which can induce death of neuron directlyCC BY · PubMed Central
Fig. 2 Inflammation in AD. In the earliest stages of AD, the formation of Aβ occurs due to abnormal cleavage of APP by β- and γ-secretases. Aβ monomers are intrinsically disordered and have a propensity to oligomerize and aggregate into Aβ plaques, which can be promoted by genetic mutations in APP or PSEN1/PSEN2 genes. The Aβ aggregates activates microglia, causing them to clear Aβ via phagocytosis and proteolysis. Yet when that clearance fails, microglia become chronically activated, which further enhances the aggregation of Aβ by improving the expression of APP and IFITM3 and increasing the release of irons, such as Zn+. This process forms a positive feedback loop, which leads to persistent, chronic inflammation. Chronically activated microglia also release proinflammatory cytokines and toxic products, including ROS and nitric oxide (NO), which amplify the immune response and lead to neurotoxicity. DAMPs released from dying neurons, including ATP, HMGB1, S100B, DNA, etc., also amplify inflammation and lead to the second positive feedback loop. Inflammatory cytokines activate kinases, leading to hyperphosphorylation of tau, the dissociation of tau monomers from microtubules, and the subsequent formation of tau tangles in the cytosol of neurons. Thus, inflammation acts as a link between the aggregation of Aβ and the accumulation of tau tangles
Fig. 2 Inflammation in AD. In the earliest stages of AD, the formation of Aβ occurs due to abnormal cleavage of APP by β- and γ-secretases. Aβ monomers are intrinsically disordered and have a propensity to oligomerize and aggregate into Aβ plaques, which can be promoted by genetic mutations in APP or PSEN1/PSEN2 genes. The Aβ aggregates activates microglia, causing them to clear Aβ via phagocytosis and proteolysis. Yet when that clearance fails, microglia become chronically activated, which further enhances the aggregation of Aβ by improving the expression of APP and IFITM3 and increasing the release of irons, such as Zn+. This process forms a positive feedback loop, which leads to persistent, chronic inflammation. Chronically activated microglia also release proinflammatory cytokines and toxic products, including ROS and nitric oxide (NO), which amplify the immune response and lead to neurotoxicity. DAMPs released from dying neurons, including ATP, HMGB1, S100B, DNA, etc., also amplify inflammation and lead to the second positive feedback loop. Inflammatory cytokines activate kinases, leading to hyperphosphorylation of tau, the dissociation of tau monomers from microtubules, and the subsequent formation of tau tangles in the cytosol of neurons. Thus, inflammation acts as a link between the aggregation of Aβ and the accumulation of tau tanglesCC BY · PubMed Central
Fig. 3 Inflammation in PD. Lewy bodies, mainly composed of α-synuclein aggregates, are one of the pathological features of PD. It is generally accepted that some genetic and environment factors lead to the aggregation of α-synuclein. Excessive α-synuclein in neuron is transported into the mitochondria, leading to the mitochondrial dysfunction that is central to the progression of PD. Mutations in mitochondrial-associated proteins like LRRK2, PINK1, PARK7, and PRKN, which are found in familial cases of PD, also induce mitochondrial dysfunction and lead to neurotoxicity. Excessive aggregation of α-synuclein or failure to clear it from the cell will result in its release either directly from the neuron or through the exosome, which activates microglia and amplifies neurotoxicity by spreading α-synuclein to the neighboring healthy DA neurons. DAMPs released from dying neurons further enhance the activation of microglia. In addition, genetic and environment factors also promote the activation of microglia and other immune cells. Activated microglia further exacerbate disease by enhancing α-synuclein pathogenicity, increasing oxidative stress, and promoting mitochondrial dysfunction
Fig. 3 Inflammation in PD. Lewy bodies, mainly composed of α-synuclein aggregates, are one of the pathological features of PD. It is generally accepted that some genetic and environment factors lead to the aggregation of α-synuclein. Excessive α-synuclein in neuron is transported into the mitochondria, leading to the mitochondrial dysfunction that is central to the progression of PD. Mutations in mitochondrial-associated proteins like LRRK2, PINK1, PARK7, and PRKN, which are found in familial cases of PD, also induce mitochondrial dysfunction and lead to neurotoxicity. Excessive aggregation of α-synuclein or failure to clear it from the cell will result in its release either directly from the neuron or through the exosome, which activates microglia and amplifies neurotoxicity by spreading α-synuclein to the neighboring healthy DA neurons. DAMPs released from dying neurons further enhance the activation of microglia. In addition, genetic and environment factors also promote the activation of microglia and other immune cells. Activated microglia further exacerbate disease by enhancing α-synuclein pathogenicity, increasing oxidative stress, and promoting mitochondrial dysfunctionCC BY · PubMed Central
Fig. 4 Inflammation in ALS. TDP-43 or SOD1 forms aggregates in the cytoplasm due to genetic and/or environmental factors, causing deleterious effects to neuron. SOD1 aggregation induces oxidative stress, while TDP-43 aggregates invade mitochondria and release mtDNA into the cytoplasm, inducing inflammation through the cGAS-STING pathway. Some mitochondria related genetic variants directly lead to dysfunction of mitochondria and oxidative stress in motor neurons. Proinflammatory cytokines and DAMPs released from damaged motor neurons activate microglia and other immune cells, leading to a persistent inflammatory attack on the motor neurons. Genetic and environment factors also promote the activation of microglia and other immune cells directly, benefiting the development of ALS
Fig. 4 Inflammation in ALS. TDP-43 or SOD1 forms aggregates in the cytoplasm due to genetic and/or environmental factors, causing deleterious effects to neuron. SOD1 aggregation induces oxidative stress, while TDP-43 aggregates invade mitochondria and release mtDNA into the cytoplasm, inducing inflammation through the cGAS-STING pathway. Some mitochondria related genetic variants directly lead to dysfunction of mitochondria and oxidative stress in motor neurons. Proinflammatory cytokines and DAMPs released from damaged motor neurons activate microglia and other immune cells, leading to a persistent inflammatory attack on the motor neurons. Genetic and environment factors also promote the activation of microglia and other immune cells directly, benefiting the development of ALSCC BY · PubMed Central
Fig. 5 Function of TREM2 in AD. TREM2 expression enhances the proliferation and migration of microglia, and improves the phagocytosis ability. At the early stage of AD development, TREM2 expression microglia surround the Aβ plaque, interact with lipidated Aβ to efficiently clear them. The surrounding microglia also prevent the spread of Aβ. But at the late stage of AD, TREM2 expression microglia fail to clear the aggregates, leading to chronic inflammation, which then attenuates the phagocytosis ability of microglia, induces tau phosphorylation and aggregation. For individuals with TREM2 mutation, the affinity of TREM2 was weakened, which inhibits the proliferation and migration of microglia, leading to the failure of microglia surrounding Aβ aggregates. TREM2 mutation also enhance the secretion of cytokines from microglia. As a result, TREM2 mutation in microglia benefits the spread of Aβ, and the phosphorylation and aggregation of tau, exacerbating AD pathology
Fig. 5 Function of TREM2 in AD. TREM2 expression enhances the proliferation and migration of microglia, and improves the phagocytosis ability. At the early stage of AD development, TREM2 expression microglia surround the Aβ plaque, interact with lipidated Aβ to efficiently clear them. The surrounding microglia also prevent the spread of Aβ. But at the late stage of AD, TREM2 expression microglia fail to clear the aggregates, leading to chronic inflammation, which then attenuates the phagocytosis ability of microglia, induces tau phosphorylation and aggregation. For individuals with TREM2 mutation, the affinity of TREM2 was weakened, which inhibits the proliferation and migration of microglia, leading to the failure of microglia surrounding Aβ aggregates. TREM2 mutation also enhance the secretion of cytokines from microglia. As a result, TREM2 mutation in microglia benefits the spread of Aβ, and the phosphorylation and aggregation of tau, exacerbating AD pathologyCC BY · PubMed Central
Fig. 6 Crosstalk between TLRs and the inflammasome pathway. TLR2, TLR4, and TLR9 are the most involved TLR receptors in neurodegenerative diseases. The binding of aggregates (e.g., Aβ, α-synuclein) or other PAMPs or DAMPs activates TLRs. Activation of TLR2 induces the MyD88-dependent pathway, which activates MAPK and NF-κB, leading to the release of proinflammatory cytokines. In addition to the MyD88-dependent pathway, TLR4 activation also transduces signal through an MyD88-independent pathway, which leads to the activation of the IRF3 transcription factor and the subsequent release of type I IFNs. TLR9 is located on internal vesicles and binds to bacterial and viral nucleic acids or endogenous CpG DNA. Activation of TLR9 induces MyD88-dependent signaling, translocation of IRF7 into the nucleus, and the release of type I IFNs. TLR activation also induces the expression of NLRP3, pro-IL-1β, and pro-IL-18, acting as the first signal (or priming signal) for the NLRP3 inflammasome pathway. A variety of stimuli, including ATP, RNA virus, and aggregates, act as the second signal (or activation signal) activating NLRP3 and inducing the assembly of NLRP3, ASC, and pro-caspase-1 into an inflammasome. This process activates caspase-1, which in turn cleaves pro-IL-1β and pro-IL-18 into IL-1β and IL-18, respectively. NLRP3 inflammasome activation also induces the maturation of GSDMD, which translocates to the plasma membrane and forms a pore through which the cleaved IL-1β and IL-18 molecules can be released into the extracellular space. In addition, GSDMD can induce an inflammatory form of cell death termed pyroptosis. The cleaved cytokines have both autocrine and paracrine effects that further amplify the inflammatory response
Fig. 6 Crosstalk between TLRs and the inflammasome pathway. TLR2, TLR4, and TLR9 are the most involved TLR receptors in neurodegenerative diseases. The binding of aggregates (e.g., Aβ, α-synuclein) or other PAMPs or DAMPs activates TLRs. Activation of TLR2 induces the MyD88-dependent pathway, which activates MAPK and NF-κB, leading to the release of proinflammatory cytokines. In addition to the MyD88-dependent pathway, TLR4 activation also transduces signal through an MyD88-independent pathway, which leads to the activation of the IRF3 transcription factor and the subsequent release of type I IFNs. TLR9 is located on internal vesicles and binds to bacterial and viral nucleic acids or endogenous CpG DNA. Activation of TLR9 induces MyD88-dependent signaling, translocation of IRF7 into the nucleus, and the release of type I IFNs. TLR activation also induces the expression of NLRP3, pro-IL-1β, and pro-IL-18, acting as the first signal (or priming signal) for the NLRP3 inflammasome pathway. A variety of stimuli, including ATP, RNA virus, and aggregates, act as the second signal (or activation signal) activating NLRP3 and inducing the assembly of NLRP3, ASC, and pro-caspase-1 into an inflammasome. This process activates caspase-1, which in turn cleaves pro-IL-1β and pro-IL-18 into IL-1β and IL-18, respectively. NLRP3 inflammasome activation also induces the maturation of GSDMD, which translocates to the plasma membrane and forms a pore through which the cleaved IL-1β and IL-18 molecules can be released into the extracellular space. In addition, GSDMD can induce an inflammatory form of cell death termed pyroptosis. The cleaved cytokines have both autocrine and paracrine effects that further amplify the inflammatory responseCC BY · PubMed Central
Fig. 7 Involvement of endothelial cells in AD. Endogenous stimuli (e.g., Aβ aggregates) or exogenous stimuli (e.g., C3a, SAA, LPS, prostaglandins, cytokines, virus proteins) can bind to its receptors in endothelial cells and induce the activation of endothelial cells. Activated endotheliocyte secrets a low level of inflammatory cytokines and chemokines, increases the expression of adhesion molecules and reduces the expression of tight junction proteins. Activation of endothelial cells also increases the expression of iNOS and NOX, which lead to oxidative stress, amplifying inflammation and damaging BBB. Secretion of cytokines and chemokine recruits peripheral immune cells, activates microglia and astrocytes in the CNS. The impaired permeability of endothelial cells and increased expression of adhesion molecules facilitate the infiltration of peripheral immune cells into the CNS, further augmenting inflammation in the CNS. As a result, stimulation on endothelial cells leads to strong inflammation in the CNS, ultimately induces Aβ and tau aggregation, and neurodegeneration
Fig. 7 Involvement of endothelial cells in AD. Endogenous stimuli (e.g., Aβ aggregates) or exogenous stimuli (e.g., C3a, SAA, LPS, prostaglandins, cytokines, virus proteins) can bind to its receptors in endothelial cells and induce the activation of endothelial cells. Activated endotheliocyte secrets a low level of inflammatory cytokines and chemokines, increases the expression of adhesion molecules and reduces the expression of tight junction proteins. Activation of endothelial cells also increases the expression of iNOS and NOX, which lead to oxidative stress, amplifying inflammation and damaging BBB. Secretion of cytokines and chemokine recruits peripheral immune cells, activates microglia and astrocytes in the CNS. The impaired permeability of endothelial cells and increased expression of adhesion molecules facilitate the infiltration of peripheral immune cells into the CNS, further augmenting inflammation in the CNS. As a result, stimulation on endothelial cells leads to strong inflammation in the CNS, ultimately induces Aβ and tau aggregation, and neurodegenerationCC BY · PubMed Central

Verification

Claims the paper makes

271 Valid · 18 Not valid · 140 Not checked · 102 Own results and interpretations

237 more claims · 122 with their cited sources checked

Create a free account to see all 531 claims and to verify the 58 references still open.

See all claims — free account
  • It may state two separate claims as one. 257
  • Probably not a substantial claim. 56

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

2 of 2

Citations

Cites

2 retracted

Show all 587 references

Cited by

See all 1,668

Metadata

Authors
Zhang, W., Xiao, D., Mao, Q., & Xia, H.
Affiliations
  • Shaanxi Normal University (CN)
  • Xijing Hospital (CN)
  • University of Utah (US)
Corresponding author
Xia, Haibin
Venue
Signal Transduction and Targeted Therapy
Published
2023-07-12
Volume
8
Issue
1
Pages
267-267
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4383894096
Cited by
1,668
References
590
Citations by year
2026: 598 · 2025: 700 · 2024: 349 · 2023: 21
FWCI
43.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81773265, 82101443)
  • Natural Science Foundation of Shaanxi Province (2023-JC-YB-160)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
neuroinflammation, neurodegeneration, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, protein aggregation, inflammatory signaling, peripheral immune cells, anti-inflammatory therapy, pathogenesis
MeSH terms
Neuroinflammatory Diseases, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Animals, Clinical Trials as Topic, Disease Models, Animal, Humans, Inflammation, Parkinson Disease, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of neuroinflammation in neurodegeneration development. https://app.cochat.ai/papers/10.1038/s41392-023-01486-5
The paper
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023). Role of neuroinflammation in neurodegeneration development. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-023-01486-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.